<DOC>
	<DOCNO>NCT00548509</DOCNO>
	<brief_summary>To investigate effect menatetrenone bone turnover postmenopausal patient osteoporosis . One month menatetrenone therapy enhance secretion gamma-carboxylation osteocalcin . Moderate increase bone resorption formation marker observe 6 month . These change may contribute fracture prevention patient osteoporosis .</brief_summary>
	<brief_title>The Effect Vitamin K2 Bone Turnover</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<mesh_term>Vitamin MK 7</mesh_term>
	<mesh_term>Menatetrenone</mesh_term>
	<criteria>Inclusion criterion : A diagnosis osteoporosis make accord Year 2000 version Diagnostic Criteria Osteoporosis propose Japanese Society Bone Mineral Research . These criterion state patient lumbar bone mineral density ( BMD ) &lt; 70 % young adult mean patient preexist osteoporotic fracture lumbar BMD &lt; 80 % young adult mean diagnose osteoporosis . Exclusion criterion : Patients secondary osteoporosis ( e.g. , due major gastrointestinal surgery , steroid therapy , rheumatoid arthritis , premenopausal bilateral oophorectomy , renal dysfunction , thyroid dysfunction ) . Patients take medication could affect bone turnover ( bisphosphonates , estrogen , calcitonin , SERM , active vitamin D3 , Warfarin ) exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>49 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>